October 2012Redx Pharma awarded £4.7M grant for new subsidiary Redx Anti-Infectives.
October 2012Redx Pharma nominated for Young Company of the Year at the Growing Business Awards.
October 2012Redx Pharma named North West's most innovative at the annual Institute of Directors Awards.
September 2012Redx Pharma announces a licence agreement that will allow Dishman Pharmaceuticals & Chemicals to use process technology patented by the Liverpool-based firm.
June 2012Dr Neil Murray, CEO of Redx Pharma, not only represents the company at BIO International Convention in Boston, but also represents Liverpool and the city's ambitions to attract major biotech business.
April 2012Redx is named Northwest Newcomer of the Year at the North West Business Masters.
April 2012Redx Oncology launches in Liverpool.
November 2011Redx receives the award for Start‐up Company of the Year at the annual BioNow Awards.
October 2011Redx secures £5.9m grant from Regional Growth Fund to support the launch of Redx Oncology.
September 2011Redx significantly expands its medicinal chemistry resource with an outsourced collaboration with SYN|thesis Medchem.
August 2011Redx and Cresset announce a collaboration on in silico screening of Redx’s pipeline of therapeutic candidates.
June 2011Redx wins the Liverpool Daily Post Regional Business Award for Knowledge Business of the Year.
April 2011Redx and Sistemic announce collaboration on micro-RNA screening of Redx's new drug candidate pipeline.
March 2011Redx announces appointment of Dr Mark Craighead from Merck as Senior Project Manager for pre-clinical development programmes.
January 2011Redx achieves first proof of concept in anti-infective programme, second proof of concept for Redox Switch technology.
December 2010Redx's September fundraising named as New Technology Deal of the Year in the Insider North West Dealmakers Awards 2010.
December 2010Key additions to Scientific Advisory Board: Dr Peter Buchan and Dr Richard Armer.
November 2010Ahead of schedule and below budget Redx team moves into bigger lab facilities within MerseyBio; four additional staff recruited.
November 2010Redx files extensive patent covering over 250 new Redox Switch analogues, with additional applications in areas such as diabetes, immune disease, anti-infectives, oncology, gastrointestinal, cardiovascular and a range of central nervous system conditions.
September 2010BPL becomes Redx Pharma Ltd (Redx) with £2.25m investment package to develop Redox Switch technology in four initial lead programmes: cardiovascular, influenza, antibiotics and neuropathic pain. New shareholders include lifesciences specialist Jon Moulton, YFM and private investors. Investment underpins strategy to identify and develop additional families of patented drug candidates to clinical readiness, prior to out-licensing to development and commercialization partners.
September 2009Completion of first in-vivo PoC for Redox Switch in cardiovascular programme. First demonstration that Redox Switch methodology can produce effective drugs in pre-clinical testing.
May 2009Wider Redox Switch patent filed, extending technology to four new therapeutic areas.
March 2009New patent filed claiming novel cardiovascular drugs effective as medicaments.
December 2008MWDA, MSIF/AFM, NWDA and private investments plus R&D grants reach funding total of £550,000.
May 2008Chemistry PoC completed for first Redox Switch application. Positive lab results obtained in-vitro in cardiovascular programme, triggering lab expansion.
August 2007BPL commenced operations within Liverpool University's MerseyBio incubator facility. NWDA/MSIF funding of £185k backs Redox Switch proof of concept studies (PoC) in chemistry and laboratory testing.
November 2005Redx Pharma forerunner Bradford Pharma Ltd (BPL) established by Peter Jackson, Derek Lindsay and Norman Molyneux (Acceleris) to develop potential new active pharmaceutical compounds, using patents licensed from Avecia Pharmaceuticals. Novel chemistry modifies existing cardiovascular drugs to enable improved "next generation" therapies.